Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Maze Therapeutics, Inc.NASDAQ: MAZE
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 17.0% from a year ago
Total equity stood at $341.7M at the end of Q1 FY2026, up 17.0% from a year earlier and down 3.7% from the prior quarter. Over 3 fiscal years it compounded at +51.8% a year.
Context
- Total equity amounted to 81.4% of total assets at the end of Q1 FY2026, down 6.3 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +17.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 354.97M USD
- Year-over-year change
- +80.3%
- 3-year CAGR
- +51.8%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 354.97M | +80.3% |
| FY2024 | 2024-12-31 | 196.9M | +1858.5% |
| FY2023 | 2023-12-31 | 10.05M | -90.1% |
| FY2022 | 2022-12-31 | 101.44M | — |
Total Equity vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +17.0% is the 5th highest of 8, against a peer median of +19.9%.
- Total equity amounts to 81.4% of total assets for MAZE, versus a peer median of 29.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
SEPNSepterna, Inc. | Sep 2026 | $427.93M USD | +10.1% | — | 69.1% |
BIOABioAge Labs, Inc. | Mar 2026 | $379.12M USD | +21.1% | — | 95.3% |
| Mar 2026 | $341.7M USD | +17.0% | +51.8% | 81.4% | |
| Mar 2026 | $148.62M USD | +2.0% | +19.3% | 29.5% | |
| Mar 2026 | $47.24M USD | +39.1% | +20.8% | 89.0% | |
| Sep 2026 | $22.58M USD | -69.3% | +38.9% | 2.7% | |
| Dec 2025 | -€29.04M EUR | +72.8% | — | 11.7% | |
| Jun 2026 | -$165.36M USD | +19.9% | — | 5.1% | |
| Peer median (excluding MAZE) | — | +19.9% | +20.8% | 29.5% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.